Allison Swartz Sells 599 Shares of Progyny (NASDAQ:PGNY) Stock

Progyny, Inc. (NASDAQ:PGNY) EVP Allison Swartz sold 599 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $17.54, for a total value of $10,506.46. Following the transaction, the executive vice president owned 88,941 shares of the company’s stock, valued at approximately $1,560,025.14. This trade represents a 0.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Allison Swartz also recently made the following trade(s):

• On Tuesday, March 3rd, Allison Swartz sold 4,657 shares of Progyny stock. The stock was sold at an average price of $17.40, for a total value of $81,031.80.
• On Monday, March 2nd, Allison Swartz sold 2,199 shares of Progyny stock. The stock was sold at an average price of $17.27, for a total value of $37,976.73.

Progyny Stock Performance

Shares of Progyny stock opened at $18.31 on Friday. The firm has a market cap of $1.50 billion, a PE ratio of 28.17, a P/E/G ratio of 1.24 and a beta of 1.01. The business’s 50 day simple moving average is $23.09 and its 200 day simple moving average is $22.92. Progyny, Inc. has a 52-week low of $16.75 and a 52-week high of $28.75.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.10. The company had revenue of $318.40 million during the quarter, compared to analysts’ expectations of $314.26 million. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The business’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period last year, the business earned $0.42 EPS. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, equities research analysts predict that Progyny, Inc. will post 0.6 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PGNY. Wellington Management Group LLP lifted its stake in Progyny by 260.9% in the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after purchasing an additional 1,621,688 shares during the last quarter. Loomis Sayles & Co. L P acquired a new position in Progyny during the fourth quarter worth approximately $19,917,000. Barclays PLC increased its position in Progyny by 79.2% during the third quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock worth $33,904,000 after buying an additional 696,447 shares during the last quarter. Ameriprise Financial Inc. raised its stake in Progyny by 37.6% in the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after buying an additional 545,431 shares during the period. Finally, Jupiter Asset Management Ltd. bought a new stake in Progyny in the second quarter valued at approximately $10,525,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on PGNY. Zacks Research cut shares of Progyny from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. KeyCorp decreased their price objective on Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, March 2nd. Jefferies Financial Group reaffirmed a “buy” rating and issued a $30.00 target price on shares of Progyny in a research report on Friday. JPMorgan Chase & Co. set a $35.00 target price on Progyny in a report on Wednesday, January 21st. Finally, Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Nine equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $29.09.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.